| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| A042302 | This study will compare progression-free survival between MRD-guided post-induction treatment strategy following zanubrutinib plus sonrotoclax therapy to continuous zanubrutinib as control. | Cancer | Hematology |
| A052101 | The study aims to compare survival between continuous treatment versus intermittent treatment that is restarted at first progression. | Cancer | Lymphoma |
| EA8231 | The goal of the study is to evaluate progression free survival between the Therapy per Physician Choice (TPC) versus Sacituzumab + Pembrolizumab regimen. Follow-up period of 5 years from the date of randomization. | Cancer | Bladder - Urothelial |
| NRG-GU014 | The goal of the study is to compare the survival of bladder-intact patients receiving a combination of radiation therapy and pembrolizumab or radiation therapy and chemotherapy. | Cancer | Bladder - Urothelial |
| S2005 | The study goal is to compare the rate of very good partial response or better in previously untreated participants with Waldenstrom's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) who are treated upfront with ibrutinib + rituximab or zanubrutinib alone versus venetoclax + rituximab regimen. | Cancer | Hematology |
| A232402CD | To compare the proportion of chemotherapy cycles with unplanned delays in patients receiving FOLFOX chemotherapy under standardized usual care (control) vs according to the PAGODA dose modification algorithm (intervention). | Cancer | Gastrointestinal |
| NRG-CC015 | This study will evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms. | Cancer | Breast |
| S2409 | This trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. | Cancer | Small Cell Lung |
| A012103 | This study will investigate whether adjuvant checkpoint inhibition offers any additional recurrence-free survival (RFS) benefit to early-stage Triple Negative Breast Cancer patients who achieve a pathologic Complete Response (pCR) after neoadjuvant chemotherapy with checkpoint inhibition. If there is no significant difference in RFS, then patients who achieve a pCR can avoid the additional toxicity, inconvenience, and cost of continued ICI treatment. | Cancer | Breast |
| A012303 | This trial will answer the question of whether, for patients classified as low risk based on pathologic Complete Response (pCR) following neoadjuvant therapy, 6 months of overall HER2 blockade is an acceptable duration (compared to 12 months). | Cancer | Breast |
| A032201 | This study compares the addition of tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). | Cancer | Renal |
| A092205 | This study compares the efficacy of cetuximab and pembrolizumab versus pembrolizumab alone in the treatment of recurrent and/or metatstatic head and neck squamous cell carcinoma. | Cancer | Head & Neck |
| EA5162 | This study aims to evaluate the safety and efficacy of osimertinib (AZD9291) among patients with non-small cell lung cancer with EGFR exon 20 insertions. | Cancer | Lung |
| NRG-GI011 | This study evaluates the overall survival rate of advanced pancreatic cancer patients who pursue dose-escalated radiation therapy versus standard treatment without dose-escalated radiation therapy at 3 years. | Cancer | Pancreatic |
| S1800E (LUNGMAP substudy) | This study is comparing a regimen of Docetaxel and Ramucirumab with or without Cemiplimab for participants with recurrent Non-Small Cell Lung Cancer, previously treated with platinum-basesd chemotherapy and immunotherapy. | Cancer | Non-Small Cell Lung |
| S1931 | This study evaluates adding surgery (radical or partial nephrectomy) to standard immunotherapy-based drug treatments for patients with metastatic renal cancer. | Cancer | Metastatic Renal |
| S2414 | This study compares disease free survival rate in patients treated with durvalumab after surgery versus observation only with early-stage non-small cell lung cancer. | Cancer | Non-Small Cell Lung |
| A072201 | This study if for patients with recurrent glioblastomas. It is looking at standard of care treatment (Lomustine) vs Anti-LAG-3 and Anti-PD-L1 Blockade. | Cancer | Glioblastoma |
| NRG GU013 | This study is for patients with high risk prostate cancer. PSA must be >20 ng/ml. Patient must have a Gleason score of 8-10. Patient cannot have metastatic disease outside of pelvic lymph nodes. No prior radiation or androgen deprivation therapy allowed. | Cancer | Prostate |
| NRG-GU011 | The purpose of this study is to look at adding Androgen deprivation therapy in patients with prostate cancer with only a few areas of metastasis. You must have had prior curative intent treatment to the prostate. | Cancer | Prostate |
| RTOG 1216 | This study is for patients with squamous cell cancer of the head and neck. It looks at after surgery adding radiation to the standard of care chemotherapy to treat the cancer. | Cancer | Head & Neck |
| S1900G (LUNGMAP substudy) | The purpose of this study is to determine if adding ramucirumab in combination with capmatinib and osimertinib is effective in treating patients with Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900J (LUNGMAP substudy) | The purpose of this study is see if Amivanatamab is effective in treating patients with MET-Amplification Positive Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900K (LUNGMAP substudy) | The purpose of this study is to determine if the use of Tepotinib with or without Ramucirumab is effective in patients with MET Exon 14 skipping positive stage 4 or recurrent non-small cell lung cancer (NSCLC).(LUNGMAP sub-study) | Cancer | Metastatic Non-Small Cell Lung |
| S2312 | This study is for patients with metastatic prostate cancer. It looks at using Cabazitaxel with or without carboplatin in patients with castrate-resistant prostate cancer. | Cancer | Prostate |
| S2303 | This study is for patients who have progressed on standard of care treatment for gastric or esophageal cancer. The study looks at adding Nivolumab to 2nd line treatment to see if it improves outcomes. | Cancer | Gastric or Esophageal |
| EA5221 | The purpose of this study is to determine in the older adult population if immunotherapy alone is better than immunotherapy + chemotherapy. Patients must be 70+ with diagnosis of Non-Small Cell Lung Cancer. | Cancer | Non-Small Cell Lung Cancer |
| NRG CC011 | This study is for patients with stage 1-3 breast cancer. Patient must be > 6 months to 5 years out from treatment and experiencing symptoms of brain fog. The study using cognitive training to try to improve brain fog symptoms. | Cancer | Breast |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.